{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:54:31Z","timestamp":1794851671176,"version":"4.9.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clinthera.2025.09.009","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T22:24:41Z","timestamp":1760394281000},"page":"1143-1148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Assessment of Adverse Events of Teplizumab: A Real-world Pharmacovigilance Study Based on the FDA Adverse Event Reporting System"],"prefix":"10.1016","volume":"47","author":[{"given":"Changjiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingshi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junli","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufen","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1675-4037","authenticated-orcid":false,"given":"Pengfei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.09.009_bib0001","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1159\/000543035","article-title":"ISPAD clinical practice consensus guidelines 2024: screening, staging, and strategies to preserve beta-cell function in children and adolescents with type 1 diabetes","volume":"97","author":"Haller","year":"2024","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.clinthera.2025.09.009_bib0002","doi-asserted-by":"crossref","first-page":"j5295","DOI":"10.1136\/bmj.j5295","article-title":"Incidence of type 1 diabetes in China, 2010-13: population based study","volume":"360","author":"Weng","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2025.09.009_bib0003","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.70012","article-title":"National burden and risk factors of diabetes mellitus in China from 1990 to 2021: results from the Global Burden of Disease study 2021","volume":"16","author":"Deng","year":"2024","journal-title":"J Diabetes"},{"key":"10.1016\/j.clinthera.2025.09.009_bib0004","doi-asserted-by":"crossref","first-page":"eabc8980","DOI":"10.1126\/scitranslmed.abc8980","article-title":"Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals","volume":"13","author":"Sims","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clinthera.2025.09.009_bib0005","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa2308743","article-title":"Teplizumab and \u03b2-cell function in newly diagnosed type 1 diabetes","volume":"389","author":"Ramos","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.09.009_bib0006","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41574-023-00849-w","article-title":"Approval of teplizumab: implications for patients","volume":"19","author":"Speake","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.clinthera.2025.09.009_bib0007","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.09.009_bib0008","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.clinthera.2025.09.009_bib0009","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2025.09.009_bib0010","doi-asserted-by":"crossref","DOI":"10.1172\/JCI177492","article-title":"Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes","volume":"134","author":"Lled\u00f3-Delgado","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2025.09.009_bib0011","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00125-018-4786-9","article-title":"Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis","volume":"62","author":"Perdigoto","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2025.09.009_bib0012","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.2337\/dc23-0675","article-title":"Teplizumab: a disease-modifying therapy for type 1 diabetes that preserves \u03b2-cell function","volume":"46","author":"Herold","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2025.09.009_bib0013","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.2337\/db13-0236","article-title":"Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Prot\u00e9g\u00e9 trial","volume":"62","author":"Hagopian","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2025.09.009_bib0014","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.4239\/wjd.v15.i8.1793","article-title":"Safety of teplizumab in patients with high-risk for diabetes mellitus type 1: a systematic review","volume":"15","author":"Buddhavarapu","year":"2024","journal-title":"World J Diabetes"},{"key":"10.1016\/j.clinthera.2025.09.009_bib0015","series-title":"Clinical Review(s) for New Drug Application 761183 Orig1s000","year":"2024"},{"key":"10.1016\/j.clinthera.2025.09.009_bib0016","series-title":"TZIELD (teplizumab-mzwv) Injection, for Intravenous Use - Prescribing Information","year":"2022"},{"key":"10.1016\/j.clinthera.2025.09.009_bib0017","doi-asserted-by":"crossref","first-page":"eaai7793","DOI":"10.1126\/sciimmunol.aai7793","article-title":"Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes","volume":"1","author":"Long","year":"2017","journal-title":"Sci Immunol"},{"key":"10.1016\/j.clinthera.2025.09.009_bib0018","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cellimm.2017.07.007","article-title":"Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes","volume":"319","author":"Long","year":"2017","journal-title":"Cell Immunol"},{"key":"10.1016\/j.clinthera.2025.09.009_bib0019","article-title":"The teplizumab saga: the challenge of not getting lost in clinical translation","author":"Chatenoud","year":"2024","journal-title":"Cold Spring Harb Perspect Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825003194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825003194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T09:09:32Z","timestamp":1764407372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825003194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0149291825003194"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.09.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of Adverse Events of Teplizumab: A Real-world Pharmacovigilance Study Based on the FDA Adverse Event Reporting System","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}